Esperion Therapeutics, Inc. (NASDAQ:ESPR) tinted gains of +1.12% (+0.6 points) to US$54.11. The volume of 0.43 Million shares climbed down over an trading activity of 722.39 Million shares. EPS ratio determined by looking at last 12 month figures is -6.75. Over the same time span, the stock marked US$82.68 as its best level and the lowest price reached was US$33.06. The corporation has a market cap of US$1.41 Billion.
Esperion Therapeutics, Inc. (NASDAQ:ESPR)’s earnings per share has been growing at a 28.1 percent rate over the past 5 year when average revenue increase was noted as 0 percent. The return on equity ratio or ROE stands at -93.8 percent while most common profitability ratio return on investment (ROI) was 0 percent. The company’s institutional ownership is monitored at 0 percent. The company’s net profit margin has achieved the current level of 0 percent and possesses 0 percent gross margin.
Daily Analyst Recommendations
A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 7 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 1 think it is Hold. Recently, analysts have updated the overall rating to 1.85. 3 analysts recommended Overweight these shares while 2 recommended Underweight, according to FactSet data.
R1 RCM Inc. (NASDAQ:RCM) is worth US$1.04 Billion and has recently risen 1.12% to US$9.02. The latest exchange of 0.6 Million shares is below its average trading activity of 885.72 Million shares. The day began at US$8.8 but the price moved to US$8.73 at one point during the trading and finally capitulating to a session high of US$9.02. The stock tapped a 52-week high of US$11 while the mean 12-month price target for the shares is US$12.75.
Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 100.22, and a price to sales ratio of 1.4. For the past 5 years, the company’s revenue has grown 44.2%, while the company’s earnings per share has grown 20.9%. With an institutional ownership near 58.6%, it carries an earnings per share ratio of -0.57.
Inside Look At Analysts Reviews
Latest analyst recommendations could offer little help to investors. The stock is a Buy among 1 brokerage firms polled by Factset Research. At present, 0 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 3 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 1.75.